secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2026-05-27T20:57:37+00:00
Accession:  0001493152-26-025441
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata shareholders approve 2021 equity plan increase to 402,214 shares
------------------------------------------------------------------------

- Elected David Hale, Steven Mento Ph.D., and Brittany Bradrick as Class II directors.
- Ratified CBIZ CPAs P.C. as independent auditor for FY2026.
- Approved issuance of shares underlying warrants (exceeding 20% of outstanding common stock).
- Approved repricing of warrants exercisable for up to 120,734 common shares.
- Approved adjournment proposal to allow sufficient votes on other proposals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000149315226025441/0001493152-26-025441-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000149315226025441/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-025441

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer